Development of Flavone Propargyl Ethers as Potent and Selective Inhibitors of Cytochrome P450 Enzymes 1A1 and 1A2

Drug Metabolism Letters

Volumn 6, Issue 4, 2013, Pages 275-284

  Sridhar, Jayalakshmi ^a   Ellis, Jamie ^a   Dupart, Patrick ^a   Liu, Jiawang ^a   Stevens, Cheryl L ^b   Foroozesh, Maryam ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b WESTERN KENTUCKY UNIVERSITY   (United States)

Author keywords

Cytochrome P450 enzyme; Flavone propargyl ethers; Mechanism based inhibition; QSAR models

Indexed keywords

2' FLAVONE PROPARGYL ETHER; 3' FLAVONE PROPARGYL ETHER; 4' FLAVONE PROPARGYL ETHER; 5 FLAVONE PROPARGYL ETHER; 6 FLAVONE PROPARGYL ETHER; 6 FLAVONONE PROPARGYL ETHER; 7 FLAVONE PROPARGYL ETHER; 7 FLAVONONE PROPARGYL ETHER; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B1; CYTOCHROME P450 INHIBITOR; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONTROLLED STUDY; DRUG BINDING; DRUG DETERMINATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT;

ALKYNES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; ETHERS; FLAVONES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84878051273     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872312811206040007     Document Type: Article

References (48)

1. Kuhnau, J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev. Nutr. Diet., 1976, 24, 117-91.
2. Arct, J.; Pytkowska, K. Flavonoids as components of biologically active cosmeceuticals. Clin. Dermatol., 2008, 26, 347-57.
3. Kale, A.; Gawande, S.; Kotwal, S. Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother. Res., 2008, 22, 567-77.
4. Zhang, S.; Yang, X.; Coburn, R. A.; Morris, M. E. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem. Pharmacol., 2005, 70, 627-39.
5. Moridani, M. Y.; Pourahmad, J.; Bui, H.; Siraki, A.; O'Brien, P. J. Dietary flavonoid iron complexes as cytoprotective superoxide radical scavengers. Free Radic. Biol. Med., 2003, 34, 243-53.
6. Inoue, T.; Sugimoto, Y.; Masuda, H.; Kamei, C. Antiallergic effect of flavonoid glycosides obtained from Mentha piperita L. Biol. Pharm. Bull., 2002, 25, 256-9.
7. Bear, W. L.; Teel, R. W. Effects of citrus flavonoids on the mutagenicity of heterocyclic amines and on cytochrome P450 1A2 activity. Anticancer Res., 2000, 20, 3609-14.
8. Hodek, P.; Trefil, P.; Stiborova, M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 2002, 139, 1-21.
9. Shimada, T.; Tanaka, K.; Takenaka, S.; Murayama, N.; Martin, M. V.; Foroozesh, M. K.; Yamazaki, H.; Guengerich, F. P.; Komori, M. Structure-Function Relationships of Inhibition of Human Cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 Flavonoid Derivatives. Chem. Res. Toxicol., 2010, 23, 1921-1935.
10. Kim, H. J.; Lee, S. B.; Park, S. K.; Kim, H. M.; Park, Y. I.; Dong, M. S. Effects of hydroxyl group numbers on the B-ring of 5, 7-dihydroxyflavones on the differential inhibition of human CYP 1A and CYP1B1 enzymes. Arch. Pharm. Res., 2005, 28, 1114-21.
11. Tsujimoto, M.; Horie, M.; Honda, H.; Takara, K.; Nishiguchi, K. The structure-activity correlation on the inhibitory effects of flavonoids on cytochrome P450 3A activity. Biol. Pharm. Bull., 2009, 32, 671-6.
12. Walle, T. Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass? Semin. Cancer Biol., 2007, 17, 354-62.
13. Zhu, N.; Lightsey, D.; Foroozesh, M.; Alworth, W.; Chaudhary, A.; Willett, K. L.; Stevens, C. K. Naphthoflavone propargyl ether inhibitors of cytochrome P450. J. Chem. Crstallogr., 2006, 36, 289-296.
14. Gobbi, S.; Cavalli, A.; Rampa, A.; Belluti, F.; Piazzi, L.; Paluszcak, A.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J. Med. Chem., 2006, 49, 4777-80.
15. Lu, Y. F.; Santostefano, M.; Cunningham, B. D.; Threadgill, M. D.; Safe, S. Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists. Biochem. Pharmacol., 1996, 51, 1077-87.
16. Kimura, Y.; Ito, H.; Ohnishi, R.; Hatano, T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem. Toxicol., 2010, 48, 429-35.
17. Otake, Y.; Walle, T. Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. Drug Metab. Dispos., 2002, 30, 103-5.
18. Roberts, D. W.; Doerge, D. R.; Churchwell, M. I.; Gamboa da Costa, G.; Marques, M. M.; Tolleson, W. H. Inhibition of extrahepatic human cytochromes P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pratense (red clover). J. Agric. Food Chem., 2004, 52, 6623-32.
19. Si, D.; Wang, Y.; Zhou, Y. H.; Guo, Y.; Wang, J.; Zhou, H.; Li, Z. S.; Fawcett, J. P. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab. Dispos., 2009, 37, 629-34.
20. Walle, U. K.; Walle, T. Bioavailable flavonoids: cytochrome P450-mediated metabolism of methoxyflavones. Drug Metab. Dispos., 2007, 35, 1985-9.
21. Quintieri, L.; Palatini, P.; Nassi, A.; Ruzza, P.; Floreani, M. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochem. Pharmacol., 2008, 75, 1426-37.
22. Zhai, S.; Dai, R.; Friedman, F. K.; Vestal, R. E. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab. Dispos., 1998, 26, 989-92.
23. Zhai, S.; Dai, R.; Wei, X.; Friedman, F. K.; Vestal, R. E. Inhibition of methoxyresorufin demethylase activity by flavonoids in human liver microsomes. Life Sci., 1998, 63, PL119-23.
24. Ortiz de Montellano, P. R. Mechanism-based inactivation of cytochrome P450: isolation and characterization of N-alkyl heme adducts. Methods Enzymol., 1991, 206, 533-40.
25. Ortiz de Montellano, P. R.; Komives, E. A. Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450. J. Biol. Chem., 1985, 260, 3330-6.
26. Ortiz de Montellano, P. R.; Kunze, K. L. Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates. J. Biol. Chem., 1980, 255, 5578-85.
27. Halpert, J. Further studies of the suicide inactivation of purified rat liver cytochrome P-450 by chloramphenicol. Mol. Pharmacol., 1982, 21, 166-72.
28. Halpert, J.; Neal, R. A. Inactivation of purified rat liver cytochrome P-450 by chloramphenicol. Mol. Pharmacol., 1980, 17, 427-31.
29. Davies, H. W.; Britt, S. G.; Pohl, L. R. Inactivation of cytochrome P-450 by 2-isopropyl-4-pentenamide and other xenobiotics leads to heme-derived protein adducts. Chem. Biol. Interact., 1986, 58, 345-52.
30. Davies, H. W.; Britt, S. G.; Pohl, L. R. Carbon tetrachloride and 2-isopropyl-4-pentenamide-induced inactivation of cytochrome P-450 leads to heme-derived protein adducts. Arch. Biochem. Biophys., 1986, 244, 387-92.
31. Davies, H. W.; Satoh, H.; Schulick, R. D.; Pohl, L. R. Immunochemical identification of an irreversibly bound heme-derived adduct to cytochrome P-450 following CCl4 treatment of rats. Biochem. Pharmacol., 1985, 34, 3203-6.
32. Foroozesh, M.; Primrose, G.; Guo, Z.; Bell, L. C.; Alworth, W. L.; Guengerich, F. P. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem. Res. Toxicol., 1997, 10, 91-102.
33. Hopkins, N. E.; Foroozesh, M. K.; Alworth, W. L. Suicide inhibitors of cytochrome P450 1A1 and P450 2B1. Biochem. Pharmacol., 1992, 44, 787-96.
34. Roberts, E. S.; Hopkins, N. E.; Foroozesh, M.; Alworth, W. L.; Halpert, J. R.; Hollenberg, P. F. Inactivation of cytochrome P450s 2B1, 2B4, 2B6, and 2B11 by arylalkynes. Drug Metab. Dispos., 1997, 25, 1242-8.
35. Sridar, C.; Kent, U. M.; Noon, K.; McCall, A.; Alworth, B.; Foroozesh, M.; Hollenberg, P. F. Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether. Drug Metab. Dispos., 2008, 36, 2234-43.
36. Strobel, S. M.; Szklarz, G. D.; He, Y.; Foroozesh, M.; Alworth, W. L.; Roberts, E. S.; Hollenberg, P. F.; Halpert, J. R. Identification of selective mechanism-based inactivators of cytochromes P-450 2B4 and 2B5, and determination of the molecular basis for differential susceptibility. J. Pharmacol. Exp. Ther., 1999, 290, 445-51.
37. Zhu, N.; Lightsey, D.; Liu, J.; Foroozesh, M.; Morgan, K. M.; Stevens, E. D.; Klein Stevens, C. L. Ethynyl and Propynylpyrene Inhibitors of Cytochrome P450. J. Chem. Crystallogr., 2010, 40, 343-352.
38. Chan, W. K.; Sui, Z.; Ortiz de Montellano, P. R. Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene. Chem. Res. Toxicol., 1993, 6, 38-45.
39. Roberts, E. S.; Hopkins, N. E.; Alworth, W. L.; Hollenberg, P. F. Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: identification of an active-site peptide. Chem. Res. Toxicol., 1993, 6, 470-9.
40. Kagawa, H.; Takahashi, T.; Ohta, S.; Harigaya, Y. Oxidation and rearrangements of flavanones by mammalian cytochrome P450. Xenobiotica, 2004, 34, 797-810.
41. Burke, M. D.; Thompson, S.; Weaver, R. J.; Wolf, C. R.; Mayer, R. T. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol., 1994, 48, 923-36.
42. Buters, J. T.; Schiller, C. D.; Chou, R. C. A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Direct fluorescence monitoring of the deethylation of 7-ethoxy-4-trifluoromethylcoumarin. Biochem. Pharmacol., 1993, 46, 1577-84.
43. DeLuca, J. G.; Dysart, G. R.; Rasnick, D.; Bradley, M. O. A direct, highly sensitive assay for cytochrome P-450 catalyzed Odeethylation using a novel coumarin analog. Biochem. Pharmacol., 1988, 37, 1731-9.
44. Sridhar, J.; Jin, P.; Liu, J.; Foroozesh, M.; Stevens, C. L. In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1. Chem. Res. Toxicol., 2010, 23, 600-7.
45. Oda, A.; Yamaotsu, N.; Hirono, S. New AMBER force field parameters of heme iron for cytochrome P450s determined by quantum chemical calculations of simplified models. J. Comput. Chem., 2005, 26, 818-26.
46. Gill, P. E.; Murray, W.; Wright, M. H. Practical Optimization. Academic Press, London: 1981.
47. McKendall, M.; Smith, T.; Ahn, K.; Ellis, J.; McGee, T.; Foroozesh, M.; Zhu, N.; Stevens, C. K. Methoxyflavone Inhibitors of Cytochrome P450. J. Chem. Crstallogr., 2008, 38, 231-237.
48. Sridhar, J.; Liu, J.; Foroozesh, M.; Stevens, C. L. Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies. Molecules, 2012, 17, 9283-305.